Age-Related Macular Degeneration Epidemiology Analysis and Forecast, 2021-2031

In 2021, there were 79,030,963 total prevalent cases of Age-Related Macular Degeneration (AMD). The cases are expected to rise at an annual growth rate (AGR) of more than 1% during the forecast period. AMD epidemiology market research report also includes a 10-year epidemiological forecast for the total prevalent cases and diagnosed prevalent cases of AMD, each segmented into early AMD and late AMD and broken down by sex and age (50–59 years, 60–69 years, 70–79 years, and 80 years and older). The total and diagnosed prevalent cases of late AMD are further segmented into late dry AMD and late wet AMD. The report also includes the total prevalent cases and diagnosed prevalent cases of geographic atrophy (GA) in these markets.

Age-related macular degeneration (AMD) is a progressive eye condition that is characterized by the gradual deterioration of the macula, which is the area of the retina responsible for central vision. AMD is the most common cause of significant irreversible vision loss among the elderly. AMD is classified into three stages: early AMD, intermediate AMD, and late AMD. Late AMD is the advanced stage of AMD, which is characterized by the presence of late dry AMD or late wet AMD. According to a meta-analysis study, the pooled prevalence of any AMD was reported to be a share among adults ages 45–85 years. In addition to the high prevalence of the condition, AMD is also associated with severe disability and has a major impact on the quality of life and emotional well-being.

For more insights, download a free report sample

What are the key segments in the AMD market?

The key segments in the AMD market are Early AMD, Late AMD, Late Dry AMD, Late Wet AMD, and GA. In 2021, the US accounted for a significant share of the total prevalent cases of early AMD in the 7MM. However, Spain is expected to have the highest AGR in the forecast period. Similarly for Late AMD, again the US has the highest number of prevalent cases among the 7MM. In case of Late Dry AMD, the UK is expected to have the highest AGR during the forecast period. In case of Late Wet AMD, the US has a significant percentage of cases, and the UK is expected to have the highest AGR. Similarly in case of GA, the UK is expected to have the highest AGR during the forecast period.

Market report overview

Scope

• This report provides an overview of the risk factors, comorbidities, and the global and historical trends for AMD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• The report also includes a 10-year epidemiological forecast for the total prevalent cases and diagnosed prevalent cases of AMD, each segmented into early AMD and late AMD and broken down by sex and age (50–59 years, 60–69 years, 70–79 years, and 80 years and older). The total and diagnosed prevalent cases of late AMD are further segmented into late dry AMD and late wet AMD. The report also includes the total prevalent cases and diagnosed prevalent cases of geographic atrophy (GA) in these markets. The forecast is supported by robust, country-specific data that was obtained from various authentic sources such as research articles published in peer-reviewed journals. In addition, in the case of data scarcity, GlobalData epidemiologists used primary market research (PMR) data wherever necessary.
• The AMD epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
• The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
• The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

• The AMD Epidemiology series will allow you to:
• Develop business strategies by understanding the trends shaping and driving the global AMD market.
• Quantify patient populations in the global AMD market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups that present the best opportunities for AMD therapeutics in each of the markets covered.
• Understand magnitude of AMD by early AMD and late AMD. Late AMD are further segmented into late dry AMD and late wet AMD.